| Name | Title | Contact Details |
|---|
Theseus is a biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies. Theseus is developing next-generation tyrosine kinase inhibitors (TKIs): "pan-variant" targeted therapies that address all major drug resistance mutations. Theseus` lead product candidate, THE-630, is a pan-variant KIT inhibitor for the treatment of patients with advanced gastrointestinal stromal tumors (GIST), whose cancer has developed resistance to earlier lines of kinase inhibitor therapy. Theseus is also developing a fourth-generation, selective epidermal growth factor receptor (EGFR) inhibitor for C797S-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer (NSCLC).
Emendo biotherapeutics develops next generation gene editing tools for genetic disorders, addressing the current technological gaps for realizing the promise of gene therapy.
Tanabe Research Laboratories U.S.A., Inc is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Cellular Dynamics International, Inc. develops and manufactures human cells in the United States of America, Europe, Japan, and internationally. The company’s proprietary iCell Operating System comprises human cells in multiple cell types (iCell products), human induced pluripotent stem cells (iPSCs), and custom iPSCs and iCell products (MyCell products). It offers iCell Cardiomyocytes, which are purified human heart cells that beat in a dish and behave just like the heart cells found in the human body for in vitro drug discovery, toxicity testing, and chemical safety, as well as in vivo cellular therapeutics research and development, and stem cell banking; and iCell Neurons that are purified human neurons typical of the forebrain for pre-clinical drug discovery, neurotoxicity testing, and disease modeling for Alzheimer’s diseases, Parkinson’s diseases, Huntington’s diseases, and others. The company also provides iCell Endothelial cells, which are interior surface blood vessel cells for use in vascular biology research, such as angiogenesis, atherosclerosis, inflammation, and other life science research; and iCell Hepatocytes that are human liver cells for pre-clinical drug discovery, hepatotoxicity testing, disease modeling, and other life science research. In addition, it offers MyCell products for making iPSCs for stem cell banking, cell modeling of specific ethnic or disease populations, and genetic engineering for in vitro research; and media and reprogramming kits for making iPSCs for limited research use. The company serves biopharmaceutical companies, government research institutions, academic and nonprofit research institutions, contract research organizations, and stem cell banks. Cellular Dynamics International, Inc. was founded in 2004 and is headquartered in Madison, Wisconsin.
US WorldMeds is a Louisville, KY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.